# Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC

> **NCT05272865** · PHASE1,PHASE2 · UNKNOWN · sponsor: **LaSanta S A S** · enrollment: 334 (estimated)

## Conditions studied

- Nausea Post Chemotherapy
- Vomiting
- Cancer Pain
- Cancer Related Pain
- Neoplasms

## Interventions

- **DRUG:** Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator

## Key facts

- **NCT ID:** NCT05272865
- **Lead sponsor:** LaSanta S A S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-15
- **Primary completion:** 2024-02-15
- **Final completion:** 2024-10-17
- **Target enrollment:** 334 (ESTIMATED)
- **Last updated:** 2023-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05272865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05272865, "Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05272865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*